UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Datensatz exportieren als...
BibTeX
Radioimmunotherapy and colorectal cancer
British journal of surgery, 2005-03, Vol.92 (3), p.264-276
Koppe, M. J.
Bleichrodt, R. P.
Oyen, W. J. G.
Boerman, O. C.
2005
Details
Autor(en) / Beteiligte
Koppe, M. J.
Bleichrodt, R. P.
Oyen, W. J. G.
Boerman, O. C.
Titel
Radioimmunotherapy and colorectal cancer
Ist Teil von
British journal of surgery, 2005-03, Vol.92 (3), p.264-276
Ort / Verlag
Chichester, UK: John Wiley & Sons, Ltd
Erscheinungsjahr
2005
Link zum Volltext
Quelle
Wiley Online Library
Beschreibungen/Notizen
Background: Despite the success of radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (Mabs) directed against tumour‐associated antigens in the treatment of non‐Hodgkin's lymphoma, therapeutic success in solid tumours has been modest. In the past decade, a dozen Mabs have been investigated clinically for their potential usefulness in RIT of colorectal cancer. Methods: The application of radiolabelled Mabs for the treatment of solid cancers is discussed, and clinical trials investigating RIT for colorectal cancer listed in the Medline and Embase databases are reviewed. Results: Uptake of radiolabelled Mabs in tumour and, consequently, the therapeutic efficacy of RIT is inversely correlated with tumour size. The bone marrow is the most important dose‐limiting organ. Twenty‐three phase I/II studies were found that investigated the feasibility and efficacy of RIT using five radionuclides and 15 Mabs against carcinoembryonic antigen, tumour‐associated glycoprotein 72, epithelial cellular adhesion molecule, A33 or colon‐specific antigen p, mainly in patients with advanced colorectal cancer. A few responses were recorded but no particular antibody construct seemed superior. Conclusion: RIT might be an effective adjuvant treatment modality in colorectal cancer. Future studies should focus on its application in patients with small‐volume or minimal residual disease. Copyright © 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. May be worthwhile for small‐volume disease
Sprache
Englisch
Identifikatoren
ISSN: 0007-1323
eISSN: 1365-2168
DOI: 10.1002/bjs.4936
Titel-ID: cdi_crossref_primary_10_1002_bjs_4936
Format
–
Schlagworte
Antibodies, Monoclonal - therapeutic use
,
Antigens, Neoplasm - metabolism
,
Biological and medical sciences
,
Carcinoembryonic Antigen - metabolism
,
Cell Adhesion Molecules - metabolism
,
Clinical Trials, Phase I as Topic
,
Clinical Trials, Phase II as Topic
,
Colorectal Neoplasms - metabolism
,
Colorectal Neoplasms - radiotherapy
,
Dose-Response Relationship, Radiation
,
Gastroenterology. Liver. Pancreas. Abdomen
,
General aspects
,
Glycoproteins - metabolism
,
Humans
,
Medical sciences
,
Membrane Glycoproteins - metabolism
,
Radioimmunotherapy - methods
,
Radioisotopes - adverse effects
,
Radioisotopes - therapeutic use
,
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
,
Tumors
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX